MA41785A - Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques - Google Patents
Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiquesInfo
- Publication number
- MA41785A MA41785A MA041785A MA41785A MA41785A MA 41785 A MA41785 A MA 41785A MA 041785 A MA041785 A MA 041785A MA 41785 A MA41785 A MA 41785A MA 41785 A MA41785 A MA 41785A
- Authority
- MA
- Morocco
- Prior art keywords
- fumarates
- compositions
- treatment
- methods
- intravenous administration
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 title 1
- 238000001990 intravenous administration Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562136431P | 2015-03-20 | 2015-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41785A true MA41785A (fr) | 2018-01-23 |
Family
ID=55702079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041785A MA41785A (fr) | 2015-03-20 | 2016-03-17 | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20180289655A1 (fr) |
| EP (1) | EP3270895A2 (fr) |
| JP (1) | JP2018508559A (fr) |
| KR (1) | KR20170138437A (fr) |
| CN (1) | CN107666905A (fr) |
| AR (1) | AR104029A1 (fr) |
| AU (1) | AU2016235743A1 (fr) |
| CA (1) | CA2979544A1 (fr) |
| EA (1) | EA201792076A1 (fr) |
| HK (1) | HK1244680A1 (fr) |
| IL (1) | IL254576A0 (fr) |
| MA (1) | MA41785A (fr) |
| MX (1) | MX2017012239A (fr) |
| TW (1) | TW201642847A (fr) |
| WO (1) | WO2016153957A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202116297A (zh) * | 2019-07-03 | 2021-05-01 | 西班牙商布爾奴爾法碼有限公司 | 組合療法之方法、組成物與套組 |
| TW202131914A (zh) | 2019-10-30 | 2021-09-01 | 西班牙商布爾奴爾法碼有限公司 | 用於神經疾病或病狀的治療之新治療方案 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| CA2526586C (fr) * | 2003-09-09 | 2010-03-16 | Biogen International Gmbh | Utilisation de derives d'acide fumarique pour traiter l'insuffisance cardiaque et l'asthme |
| CA2478458A1 (fr) | 2004-08-20 | 2006-02-20 | Michael Panzara | Traitement de la sclerose en plaques pediatrique |
| PL2316430T3 (pl) * | 2004-10-08 | 2012-11-30 | Forward Pharma As | Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego |
| EP1940382A2 (fr) | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Polytherapie a base d' esters d' acide fumarique pour le traitement de maladies autoimmunes et/ou inflammatoires |
| US20080089861A1 (en) | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
| ES2599227T3 (es) * | 2007-02-08 | 2017-01-31 | Biogen Ma Inc. | Neuroprotección en enfermedades desmielinizantes |
| EP2680010A1 (fr) | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Essais de criblage de nrf2 et procédés et compositions correspondants |
| EP2307456B1 (fr) | 2008-06-27 | 2014-10-15 | Amgen Inc. | Inhibition de l ang-2 pour traiter la sclérose en plaques |
| RU2554347C2 (ru) | 2008-08-19 | 2015-06-27 | Ксенопорт, Инк. | Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения |
| JP2012525385A (ja) | 2009-04-29 | 2012-10-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 神経変性および神経炎症の治療 |
| EP2982371A1 (fr) | 2010-02-12 | 2016-02-10 | Biogen MA Inc. | Diméthyl fumarate et l'acétate de glatiramer ou l' interféron-bêta pour le traitement de sclérose en plaques |
| JP5072128B2 (ja) * | 2011-03-31 | 2012-11-14 | 株式会社ワコール | カップ部を有する衣類 |
| US20140308244A1 (en) | 2011-08-08 | 2014-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Combination Therapy for Treatment of Inflammatory Demyelinating Disease |
| US9421273B2 (en) * | 2011-12-16 | 2016-08-23 | Biogen Ma Inc. | Silicon-containing fumaric acid esters |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| CN114146081A (zh) * | 2012-02-07 | 2022-03-08 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
| WO2014031901A1 (fr) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Procédés d'utilisation de fumarate de monométhyle et promédicaments correspondants |
| WO2014096425A2 (fr) | 2012-12-21 | 2014-06-26 | Ratiopharm Gmbh | Promédicaments de fumarate de monométhyle (mmf) |
| EP2934503B1 (fr) * | 2012-12-21 | 2019-04-10 | Biogen MA Inc. | Dérivés de fumarate substitués par du deutérium |
| CN109432073A (zh) | 2013-01-08 | 2019-03-08 | 帕萨罗杰卡有限公司 | Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途 |
| WO2014138298A1 (fr) | 2013-03-05 | 2014-09-12 | University Of Chicago | Traitement de troubles de démyélinisation |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| WO2015042294A1 (fr) * | 2013-09-18 | 2015-03-26 | Xenoport, Inc. | Compositions de nanoparticules de fumarate de diméthyle |
| CN103768045B (zh) * | 2013-10-30 | 2015-10-07 | 苏州大学附属第一医院 | 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用 |
| WO2016074684A1 (fr) * | 2014-11-11 | 2016-05-19 | Syddansk Universitet | Dérivés d'acide fumarique à usage médical |
-
2016
- 2016-03-17 MA MA041785A patent/MA41785A/fr unknown
- 2016-03-18 EP EP16715662.9A patent/EP3270895A2/fr not_active Withdrawn
- 2016-03-18 TW TW105108578A patent/TW201642847A/zh unknown
- 2016-03-18 MX MX2017012239A patent/MX2017012239A/es unknown
- 2016-03-18 KR KR1020177029928A patent/KR20170138437A/ko not_active Abandoned
- 2016-03-18 HK HK18104073.2A patent/HK1244680A1/zh unknown
- 2016-03-18 JP JP2017549232A patent/JP2018508559A/ja not_active Withdrawn
- 2016-03-18 EA EA201792076A patent/EA201792076A1/ru unknown
- 2016-03-18 AU AU2016235743A patent/AU2016235743A1/en not_active Withdrawn
- 2016-03-18 AR ARP160100749A patent/AR104029A1/es unknown
- 2016-03-18 WO PCT/US2016/023021 patent/WO2016153957A2/fr not_active Ceased
- 2016-03-18 CA CA2979544A patent/CA2979544A1/fr not_active Abandoned
- 2016-03-18 US US15/559,265 patent/US20180289655A1/en not_active Abandoned
- 2016-03-18 CN CN201680028617.1A patent/CN107666905A/zh not_active Withdrawn
-
2017
- 2017-09-18 IL IL254576A patent/IL254576A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3270895A2 (fr) | 2018-01-24 |
| AU2016235743A1 (en) | 2017-10-12 |
| EA201792076A1 (ru) | 2018-04-30 |
| IL254576A0 (en) | 2017-11-30 |
| CA2979544A1 (fr) | 2016-09-29 |
| HK1244680A1 (zh) | 2018-08-17 |
| WO2016153957A3 (fr) | 2016-11-10 |
| AR104029A1 (es) | 2017-06-21 |
| KR20170138437A (ko) | 2017-12-15 |
| WO2016153957A2 (fr) | 2016-09-29 |
| US20180289655A1 (en) | 2018-10-11 |
| MX2017012239A (es) | 2018-06-27 |
| TW201642847A (zh) | 2016-12-16 |
| JP2018508559A (ja) | 2018-03-29 |
| CN107666905A (zh) | 2018-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298689B1 (en) | Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions | |
| EP3630072A4 (fr) | Procédés et compositions pour le traitement d'une somnolence excessive | |
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| EP3390634A4 (fr) | Compositions et méthodes pour le traitement de maladies oculaires | |
| EP3448875A4 (fr) | Compositions pour le traitement de maladies | |
| EP3448987A4 (fr) | Compositions pour le traitement de maladies | |
| ME03314B (fr) | Thérapie basée sur l'arnm pour le traitement des maladies oculaires | |
| EP3481387A4 (fr) | Methodes et compositions pour le traitement de troubles épileptiques | |
| EP3389725A4 (fr) | Compositions et méthodes pour le traitement de maladies du système nerveux central | |
| EP3341391A4 (fr) | Compositions et procédés pour le traitement de la douleur | |
| EP2861246A4 (fr) | Compositions et procédés pour l'inhibition de masp-1 et/ou masp-2 et/ou masp-3 pour le traitement de divers troubles et maladies | |
| EP3390642A4 (fr) | Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13 | |
| ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
| EP2967062A4 (fr) | Déséthylhydroxychloroquine pour le traitement de maladies associées avec l'inflammation | |
| EP3352749A4 (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| EP3634431A4 (fr) | Compositions et méthodes thérapeutiques pour le traitement de l'hépatite b | |
| EP3481958A4 (fr) | Procédés et compositions de traitement de troubles et de maladies impliquant rdh12 | |
| EP3443962A4 (fr) | Dérivé de quinoline pour le traitement du cancer de l'estomac | |
| EP3389673A4 (fr) | Procédés et compositions pour l'administration de polynucléotides | |
| EP3347010A4 (fr) | Synthèse et composition d'agents thérapeutiques photodynamiques pour le traitement ciblé du cancer | |
| EP3400008A4 (fr) | Compositions thérapeutiques et méthodes pour le traitement de l'hépatite b | |
| EP3368048A4 (fr) | Méthodes et compositions pour le traitement de l'amyloïdose | |
| EP3373922A4 (fr) | Compositions et méthodes pour le traitement de l'homocystinurie | |
| EP3364965A4 (fr) | Méthodes et compositions pour le traitement de maladies neurodégénératives | |
| EP3341002A4 (fr) | Composition à base d'herbes médicinales pour le traitement de maladies maculaires liées à l'âge |